Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel) by Year
CARVYKTI (ciltacabtagene autoleucel) — U.S. sales ($M) ($M)
Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel): $1,492M in FY2025, up 71.7% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-11) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CARVYKTI (ciltacabtagene autoleucel) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 1,492 | +71.7% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 869 | +85.3% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 469 | +252.6% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 133 | – | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 0 | – | Form 10-K (filed 2024-02-16) ↗ |
Breakdown
What makes up CARVYKTI (ciltacabtagene autoleucel)
Cite this data
StockData. (2026). Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel) ($M), annual FY2021–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-carvykti-us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.